The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis.

Primary Source JAMA Dermatology Source Reference: Lin T-L, et al "Psoriasis risk in patients with atopic dermatitis treated with dupilumab" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol.2025.1578.

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...

Dermatitis. 2011;22 (2):80-97. Cosmetic Classification and Labeling The US FDA and most regulatory bodies worldwide classify products as cosmetics or drugs and do not recognize "cosmeceuticals." ...

Topical ruxolitinib cream significantly improved the signs and symptoms of atopic dermatitis (AD) while maintaining a favorable safety profile in children aged 2 to 11 years, according to the results ...

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...

Dermatitis herpetiformis (DH) is a rash often associated with celiac disease, a type of gluten-related disorder. It usually causes a very itch rash, skin discoloration, and blisters to appear in ...

Photoallergic dermatitis, however, is an immune response that can cause rashes, inflammation, and pain following sun exposure, even where the exposure is minimal.

New data were recently published showing that SHR0302, better known as ivarmacitinib, is safe and effective to use in adolescent and adult patients against atopic dermatitis, the most common ...

An updated evidence- and consensus-based living guideline on atopic eczema (AE) has been published in the Journal of the European Academy of Dermatology and Venereology. The latest edition of the ...

The global atopic dermatitis (AD) market is poised to reach $22.4bn in drug sales within the decade, buoyed by the availability of targeted therapies, market analysis suggests. A 2025 report published ...

Sun Pharmaceutical Industries Limited announced top-line results from the phase 2 clinical trial evaluating the safety and efficacy of SCD-044 (a novel, orally bioavailable sphingosine-1- phosphate ...